Clinical trial
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
NCT00329329 · Agennix, Industry · Terminated
Key facts
| NCT number | NCT00329329 |
|---|---|
| Title | Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies |
| Official title | Phase 1 Study of the Oral Platinum Agent Satraplatin in Combination With Capecitabine for the Treatment of Patients With Advanced Solid Malignancies |
| Lead sponsor | Agennix, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignancies |
| Intervention type | Drug |
| Interventions | satraplatin and capecitabine |
| Enrollment | 24 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | May 24, 2006 |
| Last update posted | Mar 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: